Lobbying client · LD-2 disclosures
Pardes Biosciences, Inc.
California
9 filings from 2 registrants · 2022–2023 · latest filed Apr 12, 2023
Reported on its behalf
$910K
every LD-2 on file
Its own filed spend
$720K
lobbying for itself
Fees to outside firms
$190K
across every firm on file
Spend over time
Every filing period on record, as reported. One column per filed period — a period with no column is a period with no filing, not a zero.
Basis · Amendments and terminations supersede the original report for the same registrant, client and period, so a revised quarter is counted once at its latest filed value. Registration-only filings carry no activity money and are excluded from these totals.
Who lobbies for them
Every outside firm that has filed on this client's behalf, by fees reported.
Reported as lobbying expenses
Money reported as spent on lobbying rather than as a fee paid to an outside firm. See the full list.
What they lobby on
Issue areas declared on the filings, ranked by how many filings name each one.
Pharmacy
PHA
9 filings
$910K on those filings
Health Issues
HCR
6 filings
$720K on those filings
Medical/Disease Research/Clinical Labs
Who did the lobbying
Every lobbyist named on this client's filings.
- John Martin Pardes Biosciences, Inc.Covered position: Principal Associate Commissioner, FDA Legislative Affairs, Sen. Tom Cotton7 filingsthrough 2023
- Jeff Ricchetti Ricchetti Incorporated4 filingsthrough 2022
Covered positions · 1 of 2 lobbyists named on these filings disclosed a prior government post. The text is reproduced exactly as filed.
The filings
Every filing on record. Each row links to its full disclosure.
This record groups every filed spelling of the client's name into one entity, so "MERCK & CO., INC." and "MERCK & CO INC" read as the same company. The grouping is the client's normalized name — organizations that file under genuinely different names appear separately. Handle: pardes-biosciences-inc.